Literature DB >> 21613249

Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis.

Deepa Hammaker1, David L Boyle, Gary S Firestein.   

Abstract

OBJECTIVES: Innate immune responses in the rheumatoid synovium contribute to inflammation and joint destruction in RA. Two IκB kinase (IKK)-related kinases, TNF receptor associated factor (TRAF) family member-associated nuclear factor κ-light-chain enhancer of activated B cells (NF-κB) activator (TANK)-binding kinase 1 (TBK1) and IKKε, potentially regulate synovitis by activating IFN response genes. These kinases induce the expression of inflammatory mediators such as C-X-C motif ligand 10 (CXCL10)/IFN-γ-induced protein 10 kDa (IP-10) in fibroblast-like synoviocytes (FLS). Since IP-10 is a promising therapeutic target in RA, we evaluated whether blocking TBK1 might be an effective way to modulate IP-10 expression.
METHODS: Wild-type (WT) and IKKε(-/-) FLS were transfected with TBK1 or control small interfering RNA (siRNA) and stimulated with polyinosinic acid : polycytidylic acid [poly(I:C)]. Gene expression was assayed using quantitative PCR. Cytokine production in culture supernatants was measured by Luminex multiplex analysis. IFN-regulatory factor (IRF3) dimerization was determined by native PAGE. IFN-β and IP-10 promoter activity was measured using luciferase reporter constructs.
RESULTS: Initial studies showed that siRNA markedly decreased TBK1 expression in cultured FLS. Poly(I:C)-induced IRF7 gene expression was inhibited in the absence of TBK1, but not IKKε. IRF3 gene expression was similar to WT cells in TBK1 or IKKε-deficient FLS. IRF3 dimerization required both TBK1 and IKKε. Surprisingly, IRF3-mediated gene and protein expression of IFN-β and IP-10 was dependent on TBK1, not IKKε. Promoter constructs showed that TBK1 decreased IP-10 gene transcription and IP-10 mRNA stability was unaffected by TBK1 deficiency.
CONCLUSION: Based on the selective regulation of IP-10 in FLS, TBK1 appears to be the optimal IKK-related kinase to target in RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613249      PMCID: PMC3306173          DOI: 10.1093/rheumatology/ker154

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  38 in total

1.  Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: common and unique pathways.

Authors:  T Iwamura; M Yoneyama; K Yamaguchi; W Suhara; W Mori; K Shiota; Y Okabe; H Namiki; T Fujita
Journal:  Genes Cells       Date:  2001-04       Impact factor: 1.891

2.  Triggering the interferon antiviral response through an IKK-related pathway.

Authors:  Sonia Sharma; Benjamin R tenOever; Nathalie Grandvaux; Guo-Ping Zhou; Rongtuan Lin; John Hiscott
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

3.  A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.

Authors:  Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tseluyko; Li-An Xu; Xiaolu Tao; Pina M Cardarelli; Heidi Leblanc; Geoff Nichol; Codrina Ancuta; Rodica Chirieac; Allison Luo
Journal:  Arthritis Rheum       Date:  2011-12-06

4.  Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription.

Authors:  M Bonnard; C Mirtsos; S Suzuki; K Graham; J Huang; M Ng; A Itié; A Wakeham; A Shahinian; W J Henzel; A J Elia; W Shillinglaw; T W Mak; Z Cao; W C Yeh
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

5.  NAK is an IkappaB kinase-activating kinase.

Authors:  Y Tojima; A Fujimoto; M Delhase; Y Chen; S Hatakeyama; K Nakayama; Y Kaneko; Y Nimura; N Motoyama; K Ikeda; M Karin; M Nakanishi
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

6.  IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli.

Authors:  Vladimir V Kravchenko; John C Mathison; Klaus Schwamborn; Frank Mercurio; Richard J Ulevitch
Journal:  J Biol Chem       Date:  2003-05-06       Impact factor: 5.157

Review 7.  Evolving concepts of rheumatoid arthritis.

Authors:  Gary S Firestein
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

8.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

9.  IRF3 mediates a TLR3/TLR4-specific antiviral gene program.

Authors:  Sean Doyle; Sagar Vaidya; Ryan O'Connell; Hajir Dadgostar; Paul Dempsey; Ting Wu; Govinda Rao; Ren Sun; Margaret Haberland; Robert Modlin; Genhong Cheng
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

Review 10.  TLR3: interferon induction by double-stranded RNA including poly(I:C).

Authors:  Misako Matsumoto; Tsukasa Seya
Journal:  Adv Drug Deliv Rev       Date:  2008-01-02       Impact factor: 15.470

View more
  20 in total

Review 1.  Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.

Authors:  Maroof Hasan; Nan Yan
Journal:  Pharmacol Res       Date:  2016-06-25       Impact factor: 7.658

2.  [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

Authors:  K W Frommer; M Geyer; G S Firestein
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 3.  The Emerging Roles of STING in Bacterial Infections.

Authors:  Fabio V Marinho; Sulayman Benmerzoug; Sergio C Oliveira; Bernhard Ryffel; V F J Quesniaux
Journal:  Trends Microbiol       Date:  2017-06-15       Impact factor: 17.079

4.  Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice.

Authors:  Maroof Hasan; Nicole Dobbs; Shaheen Khan; Michael A White; Edward K Wakeland; Quan-Zhen Li; Nan Yan
Journal:  J Immunol       Date:  2015-10-02       Impact factor: 5.422

5.  Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation.

Authors:  Xiaolei Ma; Elizabeth Helgason; Qui T Phung; Clifford L Quan; Rekha S Iyer; Michelle W Lee; Krista K Bowman; Melissa A Starovasnik; Erin C Dueber
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-22       Impact factor: 11.205

6.  Mechanism of endogenous regulation of the type I interferon response by suppressor of IκB kinase epsilon (SIKE), a novel substrate of TANK-binding kinase 1 (TBK1).

Authors:  James D Marion; Charlotte F Roberts; R Jason Call; Jonathan L Forbes; Kristina T Nelson; J Ellis Bell; Jessica K Bell
Journal:  J Biol Chem       Date:  2013-05-06       Impact factor: 5.157

7.  TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes.

Authors:  Christine V Möser; Heike Stephan; Katharina Altenrath; Katharina L Kynast; Otto Q Russe; Katrin Olbrich; Gerd Geisslinger; Ellen Niederberger
Journal:  J Neuroinflammation       Date:  2015-05-23       Impact factor: 8.322

Review 8.  Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.

Authors:  Verica Paunovic; Margaret M Harnett
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

Review 9.  The pivotal role of TBK1 in inflammatory responses mediated by macrophages.

Authors:  Tao Yu; Young-Su Yi; Yanyan Yang; Jueun Oh; Deok Jeong; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2012-12-06       Impact factor: 4.711

10.  Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.

Authors:  Yong Zhang; Hanfeng Guan; Jing Li; Zhong Fang; Wenjian Chen; Feng Li
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.